Results 61 to 70 of about 5,690,964 (274)
Molecular Oncology, EarlyView.Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker +14 more
wiley +1 more source
Cancer chemotherapy and biological response modifiers, 1990 Lung cancer was the leading cause of cancer deaths in North Carolina in 2012 (29.6%). It has been the leading cause of cancer deaths in North Carolina for over two decades. It was estimated that 8,624 people in North Carolina would be diagnosed with lung
H. Hansen, M. Ro̸rth
semanticscholar +1 more source
Molecular Oncology, EarlyView.In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen +13 more
wiley +1 more source
Solitary pulmonary nodules prediction for lung cancer patients using nomogram and machine learning [PDF]
arXiv, 2023 Lung cancer(LC) is a type of malignant neoplasm that originates in the bronchial mucosa or glands.As a clinically common nodule,solitary pulmonary nodules(SPNs) have a significantly higher probability of malignancy when they are larger than 8 mm in diameter.But there is also a risk of lung cancer when the diameter is less than 8mm,the purpose of this ...
arxiv
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients
Molecular Oncology, EarlyView.Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha +6 more
wiley +1 more source
Data-integration with pseudoweights and survey-calibration: application to developing US-representative lung cancer risk models for use in screening [PDF]
arXiv, 2023 Accurate cancer risk estimation is crucial to clinical decision-making, such as identifying high-risk people for screening. However, most existing cancer risk models incorporate data from epidemiologic studies, which usually cannot represent the target population.
arxiv
Current and Future Development in Lung Cancer Diagnosis
International Journal of Molecular Sciences, 2021 Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries. One of the reasons lung cancer is at the top of the list is that it is often not diagnosed until the cancer is at an advanced stage.
Reem Nooreldeen, H. Bach
semanticscholar +1 more source
A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini +11 more
wiley +1 more source
Nature Communications, 2021 Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor microenvironment together determine disease progression, as well as response to or escape from treatment.
Fengying Wu +24 more
semanticscholar +1 more source
Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors
Molecular Oncology, EarlyView.Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi +6 more
wiley +1 more source